@Article{duepublico_mods_00047088, author = {Baumann, Ralf and Rabaszowski, Matthaeus and Stenin, Igor and Gaertner-Akerboom, Maria and Scheckenbach, Kathrin and Wiltfang, Jens and Wagenmann, Martin}, title = {release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms}, year = {2012}, month = {Aug}, day = {01}, keywords = {IL-13; IL-31; Kinetics; Nasal allergen; Nasal secretion}, abstract = {Background: IL-31, a recently discovered member of the gp130/IL-6 cytokine family, is mainly expressed by human mast cells and T helper type 2 cells. IL-31 is a key trigger of atopic dermatitis. Recent studies also suggest a role of IL-31 in the pathogenesis of other allergic diseases including allergic rhinitis. In the present study we studied the release of IL-31 and IL-13 in allergen-challenged allergic rhinitis patients. Methods: Seven seasonal allergic volunteers underwent unilateral nasal provocation with allergen (and a control challenge) with the disc method out of the allergy season. Nasal symptom scores (rhinorrhea, itching, sneezing, obstruction) and bilateral nasal secretions were quantified before and after allergen provocation. IL-13 and IL-31 in nasal secretions and serum were measured by electrochemiluminescent immunoassay or ELISA, respectively. Results: Nasal allergen challenge induced the typical clinical symptoms and physiological changes. IL-31 and IL-13 in nasal secretions increased in four and five, respectively, volunteers at 5 h after allergen but not after control challenge. We observed correlation trends between nasal IL-31 concentrations and IL-13 concentrations (r{\thinspace}={\thinspace}0.9, p{\thinspace}={\thinspace}0.002), and IL-31 contents and symptom scores (r{\thinspace}={\thinspace}0.9, p{\thinspace}={\thinspace}0.013) 5 h after allergen provocation. No IL-31 could be detected contralaterally or systemically in the sera. Conclusions: The observed local upregulation of IL-31 mainly during the late phase reaction after nasal allergen challenge suggests a role of IL-31 in allergic rhinitis. In which way IL-31 modulates the inflammatory reaction and type 2 responses in allergic rhinitis remains to be investigated.}, note = {Clinical and Translational Allergy, 2012, 2:13; Published: 1 August 2012}, note = {The publication of this article was supported by the Publication Fund of the University of Duisburg-Essen.}, doi = {10.1186/2045-7022-2-13}, url = {https://duepublico2.uni-due.de/receive/duepublico_mods_00047088}, url = {https://doi.org/10.1186/2045-7022-2-13}, file = {:https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00046251/Baumann_et_al_Release_IL31_and_IL13.pdf:PDF}, language = {en} }